BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress C ...

GOLETA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ:ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum computing, today announced it will issue its financial results for the first quarter of fiscal 2026, which ended September 30, 2025, after the U.S. financial markets close on Wednesday, November 12, 2025. That same day, Aeluma will host a conference call at 2:00 p.m. Pacifi ...

RIDGEFIELD, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its third quarter ended September 26, 2025. Financial highlights for the third quarter of 2025: Net sales increased 9.6% to $1,021.3 million for the third quarter of 2025 from $931.5 million for the third quarter of 2024.GAAP net income was $19.1 mill ...

Core Insights - Fulcrum Therapeutics announced positive results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD), indicating potential improvements in patient outcomes [1][2][5] - The company completed enrollment in the 20 mg dose cohort and expects to provide data by the end of 2025 [1][2] - As of Q3 2025, Fulcrum reported $200.6 million in cash and equivalents, ensuring operational funding into 2028 [1][7] Recent Business Highlights - The 12 mg dose cohort results showed a dose-dependent increase in fetal hemoglobin (HbF), improvements in hemolysis markers, and trends in reducing vaso-occlusive crises (VOC) [5] - Pociredir was well-tolerated with no serious adverse events reported during the 12-week treatment period [5][9] - An open-label extension trial for pociredir is being initiated to evaluate long-term safety and response durability [5] - Fulcrum presented real-world data correlating increased HbF levels with reduced VOC rates at the ASCAT Conference [5] Financial Results for Q3 2025 - Cash, cash equivalents, and marketable securities decreased from $241.0 million at the end of 2024 to $200.6 million [6][15] - Research and development expenses were $14.3 million, slightly down from $14.6 million in Q3 2024 [6][12] - General and administrative expenses decreased to $7.6 million from $8.4 million in the same period last year [12] - The net loss for Q3 2025 was $19.6 million, an improvement from a net loss of $21.7 million in Q3 2024 [12][17]

EVERETT, Wash., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Coastal Financial Corporation (Nasdaq: CCB) (the “Company”, "Coastal", "we", "our", or "us"), the holding company for Coastal Community Bank (the “Bank”), through which it operates a community-focused bank segment ("community bank") with an industry leading banking as a service ("BaaS") segment ("CCBX"), today reported unaudited financial results for the quarter ended September 30, 2025, including net income of $13.6 million, or $0.88 per diluted common shar ...

Net Sales Increased 37% to $182 million driven by Vita Coco Coconut Water growth of 42% Net Income Increased $5 million to $24 million and Non-GAAP Adjusted EBITDA1 Increased $9 million to $32 million Company Raises Full Year Net Sales and Adjusted EBITDA Guidance NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended S ...

TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Evergold Corp. (TSX-V: EVER, WKN: A2PTHZ) (“Evergold” or the “Company”) is pleased to announce that C.J. Greig Holdings Ltd., a company wholly-owned by C.J. “Charlie” Greig, a director of the Company and Evergold’s Chief Exploration Officer (the “Investor”), has agreed to subscribe for up to $350,000 (the “Offering”) of an unsecured convertible debenture (the “Debenture”). The Debenture bears interest at a rate of 7.5% per annum and will mature on December 31, 2026 ...

SATO Corporation, Stock Exchange Release 29 October 2025 at 1:00 pm SATO Corporation’s financial reports and AGM in 2026In 2026, SATO will publish its financial reports according to the following schedule: 6 February 2025Financial Statements Release for 20258 May 2026Interim Report for 1 January–31 March 2026 (Q1)14 July 2026Half-year Report for 1 January–30 June 2026 (H1)23 October 2026Interim Report for 1 January–30 September 2026 (Q3) The Annual Report for 2025 will be published on SATO’s website at www ...

Group 1 - Mowi has acquired a controlling stake in Nova Sea from Vigner Olaisen AS, as announced on 21 October 2025 [1] - 30% of the purchase price for the acquisition has been settled through the issuance of new shares in Mowi, totaling 10,179,505 new shares issued to Vigner Olaisen AS [2] - Following the share issuance, Mowi's new share capital is NOK 3,954,679,470, divided into 527,290,596 shares, each with a nominal value of NOK 7.50 [2]

Core Viewpoint - Navient has released its financial results for the third quarter of 2025, indicating ongoing efforts to manage the cost of higher education for students and families [1]. Financial Results - The complete financial results for the third quarter of 2025 are available on Navient's investor website [1]. - A live audio webcast discussing these results will be hosted by the CEO and CFO on October 29, 2025, at 8 a.m. ET [1]. Company Overview - Navient focuses on helping students and families manage higher education costs through responsible lending, flexible refinancing, and trusted servicing [3]. - The company emphasizes creating long-term value for customers and investors, supported by decades of portfolio management expertise [3].